Renal Sympathetic Denervation Suppresses De Novo Podocyte Injury and Albuminuria in Rats With Aortic Regurgitation
Authors:
- 20 March 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 125 (11) , 1402-1413
Abstract
Background—: The presence of chronic kidney disease is a significant independent risk factor for poor prognosis in patients with chronic heart failure. However, the mechanisms and mediators underlying this interaction are poorly understood. In this study, we tested our hypothesis that chronic cardiac volume overload leads to de novo renal dysfunction by coactivating the sympathetic nervous system and renin-angiotensin system in the kidney. We also examined the therapeutic potential of renal denervation and renin-angiotensin system inhibition to suppress renal injury in chronic heart failure. Methods and Results—: Sprague-Dawley rats underwent aortic regurgitation and were treated for 6 months with vehicle, olmesartan (an angiotensin II receptor blocker), or hydralazine. At 6 months, albuminuria and glomerular podocyte injury were significantly increased in aortic regurgitation rats. These changes were associated with increased urinary angiotensinogen excretion, kidney angiotensin II and norepinephrine (NE) levels, and enhanced angiotensinogen and angiotensin type 1a receptor gene expression and oxidative stress in renal cortical tissues. Aortic regurgitation rats with renal denervation had decreased albuminuria and glomerular podocyte injury, which were associated with reduced kidney NE, angiotensinogen, angiotensin II, and oxidative stress. Renal denervation combined with olmesartan prevented podocyte injury and albuminuria induced by aortic regurgitation. Conclusions—: In this chronic cardiac volume-overload animal model, activation of the sympathetic nervous system augments kidney renin-angiotensin system and oxidative stress, which act as crucial cardiorenal mediators. Renal denervation and olmesartan prevent the onset and progression of renal injury, providing new insight into the treatment of cardiorenal syndrome.Keywords
This publication has 57 references indexed in Scilit:
- Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species—ERK/JNK pathwaysHypertension Research, 2010
- Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathyNephrology Dialysis Transplantation, 2010
- Mineralocorticoid Receptor Blockade Enhances the Antiproteinuric Effect of an Angiotensin II Blocker through Inhibiting Podocyte Injury in Type 2 Diabetic RatsThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Sympathetic nerves and the progression of chronic kidney disease during 5/6 nephrectomy: Studies in sympathectomized ratsClinical and Experimental Pharmacology and Physiology, 2009
- Augmentation of endogenous intrarenal angiotensin II levels in Val5-ANG II-infused ratsAmerican Journal of Physiology-Renal Physiology, 2009
- Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuriaJournal Of Hypertension, 2008
- Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseasesJournal of the American Society of Hypertension, 2008
- Attenuation of NADPH Oxidase Activation and Glomerular Filtration Barrier Remodeling With Statin TreatmentHypertension, 2008
- Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failureJournal of Molecular and Cellular Cardiology, 2007
- The Intrarenal Renin-Angiotensin System: From Physiology to the Pathobiology of Hypertension and Kidney DiseasePharmacological Reviews, 2007